BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• BRAF(V600E) mutations occur in ~10% of colorectal cancers (CRCs) and are linked to poor prognosis.
• BRAF inhibitors like vemurafenib show limited efficacy due to feedback activation of EGFR signaling, promoting proliferation.
• Targeting BRAF(V600E)-mutant CRC requires strategies to overcome resistance mechanisms.

Purpose of the Study:

• To investigate the synergistic effects of dabrafenib (BRAF inhibitor) and cetuximab (EGFR inhibitor) on BRAF(V600E)-mutant CRC stem cells.
• To elucidate the underlying mechanisms responsible for the combined therapeutic efficacy.
• To assess the impact on cell viability, apoptosis, cell cycle, and stemness.

Main Methods:

• Cell viability assays
• Flow cytometry for apoptosis and cell cycle analysis
• Sphere-forming assays to evaluate stem cell capacity
• Western blot analysis to investigate signaling pathways (PTEN/Src/c-Myc)

Main Results:

• Dabrafenib and cetuximab demonstrated synergistic effects in reducing cell viability in BRAF(V600E)-mutant HT-29 cells.
• The combination therapy induced enhanced apoptosis and cell cycle arrest.
• Combined treatment inhibited cancer stem cell capacities.
• The PTEN/Src/c-Myc pathway was identified as a potential mediator of the observed synergism.

Conclusions:

• The combination of dabrafenib and cetuximab exhibits significant antitumor activity against BRAF(V600E)-mutant CRC cells.
• This dual-targeted therapy effectively reduces cancer stem cell populations.
• The findings suggest a promising therapeutic strategy for BRAF(V600E)-mutant CRC by targeting both BRAF and EGFR signaling pathways.